Calliditas Therapeutics A... (CALT)
NASDAQ: CALT
· Real-Time Price · USD
40.00
-0.04 (-0.10%)
At close: Sep 20, 2024, 10:00 PM
Calliditas Therapeutics AB (publ) Income Statement
Financials in SEK. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 559.78M | 295.48M | 451.56M | 294.59M | 269.38M | 191.35M | 429.04M | 260.06M | 64.05M | 49.73M | 31.18M | 198.17M | n/a | n/a |
Cost of Revenue | 53.45M | 14.01M | 22.3M | 14.92M | 14.21M | 9.03M | 7.88M | 4.32M | 2.38M | 614K | n/a | n/a | n/a | n/a |
Gross Profit | 506.33M | 281.47M | 429.26M | 279.67M | 255.17M | 182.32M | 421.16M | 255.73M | 61.66M | 49.12M | 31.18M | 198.17M | n/a | n/a |
Operating Income | -34.2M | -203.83M | 29.42M | -159.57M | -75.17M | -184.1M | 77.35M | -36.23M | -209.84M | -214.5M | -222.13M | 7.86M | -159.4M | -150.78M |
Interest Income | n/a | n/a | 16.16M | n/a | 4.51M | n/a | 64.2M | 20.27M | 17.75M | n/a | 14.42M | n/a | n/a | 14.61M |
Pretax Income | -42.66M | -247.32M | -14.26M | -164.08M | -70.66M | -208.02M | 10.07M | -15.96M | -192.09M | -211.43M | -218.47M | 6.48M | -165.21M | -136.17M |
Net Income | -47.48M | -246.16M | -18.37M | -168.36M | -91.93M | -187.53M | -3.68M | -9.11M | -192.43M | -207.05M | -219.17M | 6.45M | -159.84M | -125.45M |
Selling & General & Admin | 419.82M | 342.17M | 293.17M | 259.17M | 268.62M | 239.77M | 272.92M | 187.14M | 172.18M | 142.43M | 151.71M | 95.37M | 84.37M | 58.78M |
Research & Development | 120.72M | 150.61M | 106.68M | 179.91M | 88.99M | 126.65M | 102.24M | 102.88M | 96.29M | 113.34M | 100.29M | 92.1M | 75.02M | 90.08M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 13.51M | 1.95M | 3.04M | 1.71M | 1.31M | 2.84M | 7K | 1.93M |
Operating Expenses | 540.53M | 485.3M | 399.84M | 439.24M | 330.34M | 366.43M | 388.67M | 291.96M | 271.51M | 257.49M | 253.31M | 190.31M | 159.4M | 150.78M |
Interest Expense | 11.16M | 43.5M | n/a | 4.51M | n/a | 27.94M | n/a | 20.27M | 17.75M | 3.07M | n/a | 1.38M | n/a | n/a |
Selling & Marketing Expenses | 252.99M | 240.15M | 198.54M | 170.5M | 191.47M | 167.22M | 191.89M | 116.14M | 113.27M | 93.9M | 70.64M | 31.17M | 58.37M | 19.43M |
Cost & Expenses | 593.98M | 499.31M | 422.14M | 454.16M | 344.56M | 375.45M | 396.55M | 296.28M | 273.89M | 258.1M | 253.31M | 190.31M | 159.4M | 150.78M |
Income Tax Expense | 4.82M | -1.16M | 4.11M | 4.28M | 21.27M | -20.49M | 13.75M | -6.85M | 339K | -4.39M | 199K | 31K | -2.14M | -9.3M |
Shares Outstanding (Basic) | 26.84M | 26.84M | 26.84M | 26.84M | 26.84M | 26.84M | 26.63M | 13.31M | 13.3M | 13.1M | 13.09M | 12.77M | 12.49M | 12.49M |
Shares Outstanding (Diluted) | 26.84M | 26.84M | 26.84M | 26.84M | 26.84M | 26.84M | 26.63M | 13.31M | 13.3M | 13.1M | 13.09M | 12.89M | 12.49M | 12.49M |
EPS (Basic) | -1.76 | -9.18 | -0.68 | -6.28 | -3.42 | -6.98 | -0.14 | -0.68 | -14.48 | -15.82 | -16.74 | 0.50 | -12.8 | -10.04 |
EPS (Diluted) | -1.76 | -9.18 | -0.68 | -6.28 | -3.42 | -6.98 | -0.14 | -0.68 | -14.48 | -15.82 | -16.74 | 0.50 | -12.8 | -10.04 |
EBITDA | -31.5M | -202.77M | 31M | -159.05M | -75.17M | -180.07M | 77.81M | -36.04M | -209.84M | -208.37M | -203.94M | 7.87M | -159.39M | -150.77M |
EBIT | -31.5M | -203.83M | 31M | -159.57M | -75.17M | -180.07M | 77.81M | -36.23M | -209.84M | -208.37M | -203.94M | 7.86M | -159.4M | -150.78M |
Depreciation & Amortization | 2.7M | 1.06M | 1.06M | 526.5K | 526.5K | 526.5K | 526.5K | 186.75K | 186.75K | 186.75K | 186.75K | 9.25K | 9.25K | 9.25K |